Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Abasria

- PMLiVE

Sanofi signs agreement worth up to $750m for Maze’s Pompe disease drug

The candidate has recently cleared its first phase 1 clinical trial

- PMLiVE

Eli Lilly to sell low blood sugar drug Baqsimi to Amphastar in deal worth over $1bn

The drug is available in 27 markets, with worldwide sales totalling over $139m in 2022

- PMLiVE

New report reveals ‘major’ financial burdens faced by atopic dermatitis patients

The report, commissioned by Sanofi, analyses the economic impact of the condition

- PMLiVE

Novo Nordisk and Aspect Biosystems partner in billion dollar deal for diabetes treatments

The deal to develop a new class of disease-modifying treatments could be worth up to $2.6bn

- PMLiVE

Positive results for Sanofi’s haemophilia therapy published in The Lancet

Fitusiran reduced annualised bleeding rates by 90% compared to control arms

- PMLiVE

Boehringer Ingelheim and Covant to collaborate on cancer immunotherapies

The deal to develop a small-molecule inhibitor could be worth over $480m

- PMLiVE

Novo Nordisk and Dewpoint partner on insulin resistance drug candidates

Insulin resistance affects around 15.5% to 46.5% of the world’s population

- PMLiVE

Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children

Dupixent is now the first and only targeted medicine in the EU for this patient population

- PMLiVE

Sanofi/Regeneron’s Dupixent shows promise in atopic hand and foot dermatitis

Atopic dermatitis affects over 26 million people in the US alone

- PMLiVE

Sanofi to cut US insulin prices by up to 78% in January 2024

The announcement follows similar moves by Novo Nordisk and Eli Lilly earlier this month

- PMLiVE

Novo Nordisk to cut US insulin prices by up to 75% in January 2024

The decision comes just weeks after Eli Lilly announced a similar series of price cuts

- PMLiVE

Sanofi to acquire Provention Bio in deal worth $2.9bn

The merger includes recently-approved type 1 diabetes prevention therapy Tzield

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links